RU2011135234A - Применение стромальных стволовых клеток жировой ткани для лечения свищей - Google Patents

Применение стромальных стволовых клеток жировой ткани для лечения свищей Download PDF

Info

Publication number
RU2011135234A
RU2011135234A RU2011135234/10A RU2011135234A RU2011135234A RU 2011135234 A RU2011135234 A RU 2011135234A RU 2011135234/10 A RU2011135234/10 A RU 2011135234/10A RU 2011135234 A RU2011135234 A RU 2011135234A RU 2011135234 A RU2011135234 A RU 2011135234A
Authority
RU
Russia
Prior art keywords
stem cells
stromal stem
fistula
adipose
derived
Prior art date
Application number
RU2011135234/10A
Other languages
English (en)
Other versions
RU2608641C2 (ru
Inventor
МИГЕЛЬ Мария Хема ФЕРНАНДЕС
ДЕ ЛА ПЕНЬЯ Мануэль Анхель ГОНСАЛЕС
КАСТРО Роза Анна ГАРСИЯ
АРРАНС Мариано ГАРСИЯ
ОЛЬМО Дамиан ГАРСИЯ
Original Assignee
Сельерикс, С.Л.
Универсидад Аутонома Де Мадрид
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37116048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2011135234(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Сельерикс, С.Л., Универсидад Аутонома Де Мадрид filed Critical Сельерикс, С.Л.
Publication of RU2011135234A publication Critical patent/RU2011135234A/ru
Application granted granted Critical
Publication of RU2608641C2 publication Critical patent/RU2608641C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/10—Polypeptides; Proteins
    • A61L24/106—Fibrin; Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/16—Bone cutting, breaking or removal means other than saws, e.g. Osteoclasts; Drills or chisels for bones; Trepans
    • A61B17/1659—Surgical rasps, files, planes, or scrapers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/32—Surgical cutting instruments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A61L24/0015—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A61L27/3869—Epithelial tissues other than skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3895—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/32—Surgical cutting instruments
    • A61B2017/320004—Surgical cutting instruments abrasive
    • A61B2017/320008—Scrapers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/64—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/56—Fibrin; Thrombin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Botany (AREA)
  • Transplantation (AREA)
  • Surgery (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)

Abstract

1. Применение полученных из жировой ткани стромальных стволовых клеток в производстве фармацевтической композиции для лечения свища у субъекта, где указанные полученные из жировой ткани стромальные стволовые клетки получены из жировой ткани субъекта, которого предстоит лечить.2. Применение по п.1, где указанные полученные из жировой ткани стромальные стволовые клетки образуют композицию, содержащую полученные из жировой ткани стромальные стволовые клетки, где, по меньшей мере, приблизительно 50% полученных из жировой ткани стромальных стволовых клеток, образующих композицию, экспрессируют маркеры CD9, CD10, CD13, CD29, CD44, CD49A, CD51, CD54, CD55, CD58, CD59, CD90 и CD105.3. Применение по п.1, где указанные полученные из жировой ткани стромальные стволовые клетки образуют композицию, содержащую полученные из жировой ткани стромальные стволовые клетки, где, по меньшей мере, приблизительно 85% полученных из жировой ткани стромальных стволовых клеток, образующих композицию, экспрессируют маркеры CD9, CD10, CD13, CD29, CD44, CD49A, CD51, CD54, CD55, CD58, CD59, CD90 и CD105.4. Применение по п.1, где указанные полученные из жировой ткани стромальные стволовые клетки образуют композицию, содержащую полученные из жировой ткани стромальные стволовые клетки, где, по меньшей мере, приблизительно 95% полученных из жировой ткани стромальных стволовых клеток, образующих композицию, экспрессируют маркеры CD9, CD10, CD13, CD29, CD44, CD49A, CD51, CD54, CD55, CD58, CD59, CD90 и CD105.5. Применение по п.1, где указанные полученные из жировой ткани стромальные стволовые клетки образуют композицию, содержащую полученные из жировой ткани стромальные стволовые клетки, где, по меньшей мере, приблизительно 99% полученных из жирово

Claims (28)

1. Применение полученных из жировой ткани стромальных стволовых клеток в производстве фармацевтической композиции для лечения свища у субъекта, где указанные полученные из жировой ткани стромальные стволовые клетки получены из жировой ткани субъекта, которого предстоит лечить.
2. Применение по п.1, где указанные полученные из жировой ткани стромальные стволовые клетки образуют композицию, содержащую полученные из жировой ткани стромальные стволовые клетки, где, по меньшей мере, приблизительно 50% полученных из жировой ткани стромальных стволовых клеток, образующих композицию, экспрессируют маркеры CD9, CD10, CD13, CD29, CD44, CD49A, CD51, CD54, CD55, CD58, CD59, CD90 и CD105.
3. Применение по п.1, где указанные полученные из жировой ткани стромальные стволовые клетки образуют композицию, содержащую полученные из жировой ткани стромальные стволовые клетки, где, по меньшей мере, приблизительно 85% полученных из жировой ткани стромальных стволовых клеток, образующих композицию, экспрессируют маркеры CD9, CD10, CD13, CD29, CD44, CD49A, CD51, CD54, CD55, CD58, CD59, CD90 и CD105.
4. Применение по п.1, где указанные полученные из жировой ткани стромальные стволовые клетки образуют композицию, содержащую полученные из жировой ткани стромальные стволовые клетки, где, по меньшей мере, приблизительно 95% полученных из жировой ткани стромальных стволовых клеток, образующих композицию, экспрессируют маркеры CD9, CD10, CD13, CD29, CD44, CD49A, CD51, CD54, CD55, CD58, CD59, CD90 и CD105.
5. Применение по п.1, где указанные полученные из жировой ткани стромальные стволовые клетки образуют композицию, содержащую полученные из жировой ткани стромальные стволовые клетки, где, по меньшей мере, приблизительно 99% полученных из жировой ткани стромальных стволовых клеток, образующих композицию, экспрессируют маркеры CD9, CD10, CD13, CD29, CD44, CD49A, CD51, CD54, CD55, CD58, CD59, CD90 и CD105.
6. Применение по п.5, где менее чем приблизительно 5% полученных из жировой ткани стромальных стволовых клеток, образующих композицию, экспрессируют маркеры CD34, CD11b, CD14, CD15, CD16, CD31, CD34, CD45, CD49f, CD102, CD104, CD106 и/или CD133.
7. Применение по п.1, где композиция, содержащая полученные из жировой ткани стромальные стволовые клетки, дополнительно содержит раствор Рингера и HSA.
8. Применение по п.1, где концентрация полученных из жировой ткани стромальных стволовых клеток, образующих композицию, составляет, по меньшей мере, приблизительно 10·106 клеток/мл.
9. Применение по п.8, где концентрация полученных из жировой ткани стромальных стволовых клеток, образующих композицию, составляет, по меньшей мере, приблизительно 20·106 клеток/мл.
10. Применение по п.1, где композиция, содержащая полученные из жировой ткани стромальные стволовые клетки, дополнительно содержит адгезивное вещество.
11. Применение по п.10, где указанное адгезивное вещество представляет собой фибриновый клей или гель.
12. Применение по п.1, где полученная из жировой ткани стромальная стволовая клетка экспрессирует маркеры c-Kit, виментин и CD90, и не экспрессируют маркеры CD34, фактор VIII, альфа-актин, десмин, S-100 и кератин.
13. Применение по п.1, где полученная из жировой ткани стромальная стволовая клетка экспрессирует маркеры CD9, CD10, CD13, CD29, CD44, CD49A, CD51, CD54, CD55, CD58, CD59, CD90 и CD105 и не экспрессирует маркеры CD34, CD11b, CD14, CD15, CD16, CD31, CD34, CD45, CD49f, CD102, CD104, CD106 и/или CD133.
14. Применение по п.1, где указанная фармацевтическая композиция доставляется в качестве первой дозы к закрытому внутреннему отверстию свищевого канала после закрывания внутреннего отверстия швом.
15. Применение по п.14, где указанная фармацевтическая композиция доставляется в качестве первой дозы к одному или более сайтам на стенках свищевого канала после закрывания внутреннего отверстия свищевого канала швом.
16. Применение по п.14, где первая доза указанной фармацевтической композиции содержит, по меньшей мере, приблизительно 10·106 полученных из жировой ткани стромальных стволовых клеток.
17. Применение по п.15 или 16, где вторая доза указанной фармацевтической композиции доставляется к закрытому швом внутреннему отверстию или одному или более сайтам на стенках свищевого канала после первой дозы указанной фармацевтической композиции.
18. Применение по п.17, где вторая доза указанной фармацевтической композиции содержит, по меньшей мере, приблизительно 20·106 полученных из жировой ткани стромальных стволовых клеток.
19. Применение по п.18, где указанные полученные из жировой ткани стромальные стволовые клетки содержатся в шве.
20. Применение по п.1, где указанные полученные из жировой ткани стромальные стволовые клетки доставляются к материалу для заполнения свищевого канала.
21. Применение по п.20, где указанный материал представляет собой полимер на основе фибрина или адгезивное вещество, такое как фибриновый клей или гель.
22. Применение по п.1, где свищ представляет собой аноректальный свищ, свищ заднего прохода, каловый свищ, артериовенозную фистулу, желчный свищ, шеечный свищ, кранио-пазушную фистулу, межкишечный свищ, кишечно-кожный свищ, тонкокишечно-влагалищный свищ, желудочный свищ, маточно-перитонеальный свищ, перилимфатический свищ, артериовенозную фистулу легкого, прямокишечно-влагалищный свищ, пупочный свищ, трахеопищеводный свищ или мочепузырно-влагалищный свищ.
23. Применение по п.22, где свищ представляет собой аноректальный свищ, межкишечный свищ, кишечно-кожный свищ, прямокишечно-влагалищный свищ или мочепузырно-влагалищный свищ.
24. Применение по п.1, где указанную фармацевтическую композицию вводят субъекту, проходящему лечение, в сочетании с терапевтическим средством.
25. Применение по п.24, где указанное терапевтическое средство вводят системно или местно в сайт шва.
26. Применение по п.24, где указанная фармацевтическая композиция содержит указанное терапевтическое средство.
27. Применение по п.26, где указанное терапевтическое средство вводят отдельно относительно указанной фармацевтической композиции, содержащей указанные полученные из жировой ткани стромальные стволовые клетки.
28. Применение по п.26, где указанное терапевтическое средство представляет собой противовоспалительное средство, иммуносупрессивное средство, биологическое средство, антибиотик или противодиарейное средство.
RU2011135234A 2005-06-24 2011-08-23 Применение стромальных стволовых клеток жировой ткани для лечения свищей RU2608641C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/167,061 US20060045872A1 (en) 2004-08-25 2005-06-24 Use of adipose tissue-derived stromal stem cells in treating fistula
US11/167,061 2005-06-24

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2008102643/10A Division RU2435846C2 (ru) 2005-06-24 2006-05-16 Применение стромальных стволовых клеток жировой ткани для лечения свищей

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2016152229A Division RU2744977C2 (ru) 2005-06-24 2016-12-29 Применение стромальных стволовых клеток жировой ткани для лечения свищей

Publications (2)

Publication Number Publication Date
RU2011135234A true RU2011135234A (ru) 2013-02-27
RU2608641C2 RU2608641C2 (ru) 2017-01-23

Family

ID=37116048

Family Applications (3)

Application Number Title Priority Date Filing Date
RU2008102643/10A RU2435846C2 (ru) 2005-06-24 2006-05-16 Применение стромальных стволовых клеток жировой ткани для лечения свищей
RU2011135234A RU2608641C2 (ru) 2005-06-24 2011-08-23 Применение стромальных стволовых клеток жировой ткани для лечения свищей
RU2016152229A RU2744977C2 (ru) 2005-06-24 2016-12-29 Применение стромальных стволовых клеток жировой ткани для лечения свищей

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2008102643/10A RU2435846C2 (ru) 2005-06-24 2006-05-16 Применение стромальных стволовых клеток жировой ткани для лечения свищей

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2016152229A RU2744977C2 (ru) 2005-06-24 2016-12-29 Применение стромальных стволовых клеток жировой ткани для лечения свищей

Country Status (23)

Country Link
US (10) US20060045872A1 (ru)
EP (7) EP3176255B1 (ru)
JP (5) JP2008546397A (ru)
KR (1) KR20080036588A (ru)
CN (2) CN101263224A (ru)
AU (1) AU2006261383B2 (ru)
BR (1) BRPI0613811B8 (ru)
CA (1) CA2613457C (ru)
CY (3) CY1116764T1 (ru)
DK (4) DK3176254T3 (ru)
ES (6) ES2696536T3 (ru)
HU (3) HUE036590T2 (ru)
IL (1) IL188378A (ru)
LT (3) LT2944688T (ru)
LU (1) LUC00085I2 (ru)
NL (1) NL300953I2 (ru)
NZ (2) NZ565246A (ru)
PL (3) PL3176255T3 (ru)
PT (3) PT2292737E (ru)
RU (3) RU2435846C2 (ru)
SG (1) SG166770A1 (ru)
SI (3) SI2944688T1 (ru)
WO (1) WO2006136244A2 (ru)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7803787B2 (en) * 2002-10-16 2010-09-28 Arthrodynamic Technologies, Animal Health Division, Inc. Composition and method for treating connective tissue damage by transmucosal administration
US8455458B2 (en) 2002-10-16 2013-06-04 Arthrodynamic Technologies, Animal Health Division, Inc. Composition and method for treating connective tissue damage
US20060045872A1 (en) * 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
JP2008541238A (ja) 2005-05-05 2008-11-20 アーキペラゴ ホールディングス インコーポレイテッド 値段が付けられていない注文のオークション及び転送
US20070027543A1 (en) * 2005-08-01 2007-02-01 Gimble Jeffrey M Use of adipose tissue-derived stromal cells in spinal fusion
EP3184630B1 (en) 2005-09-23 2019-07-17 TiGenix, S.A.U. Cell populations having immunoregulatory activity, method for isolation and uses
WO2007039986A1 (ja) * 2005-10-05 2007-04-12 Osaka University 脂肪組織由来細胞から膵内分泌細胞を得る方法
EP1956986B1 (en) * 2005-12-02 2017-03-29 Cook Medical Technologies LLC Devices, systems, and methods for occluding a defect
US20090209031A1 (en) * 2006-01-26 2009-08-20 Tyco Healthcare Group Lp Medical device package
WO2007089798A2 (en) * 2006-01-30 2007-08-09 University Of Virginia Patent Foundation Methods of preparing and characterizing mesenchymal stem cell aggregates and uses thereof
US20070224173A1 (en) * 2006-03-21 2007-09-27 Koullick Edouard A Nonexpansion Protocol for Autologous Cell-Based Therapies
WO2008024996A2 (en) * 2006-08-24 2008-02-28 Johnstone Brian H Production of neural protective and regenerative factors from stem cells and treatment of nervous system conditions therewith
US8835170B2 (en) * 2006-10-06 2014-09-16 University Of Virginia Patent Foundation Methods and compositions useful for diabetic wound healing
KR20080103637A (ko) * 2007-05-25 2008-11-28 주식회사 알앤엘바이오 지방유래 줄기세포를 함유하는 사지말단부 허혈성 질환의세포치료용 조성물
US9186375B2 (en) 2007-06-21 2015-11-17 Arthrodynamic Technologies, Animal Health Division, Inc. Glycosaminoglycan compositions in combination with stem cells
AU2014227541B2 (en) * 2007-09-19 2015-10-01 Pluristem Ltd. Methods of Treating Inflammatory Colon Diseases
RU2515156C2 (ru) * 2008-05-27 2014-05-10 Плуристем Лтд. Способы лечения воспалительных заболеваний ободочной кишки
WO2009152084A2 (en) * 2008-06-11 2009-12-17 Cell4Vet Llc Adipose tissue-derived stem cells for veterinary use
KR101712560B1 (ko) 2008-06-24 2017-03-06 바이오엑티브 써지컬, 아이엔씨. 줄기 세포 또는 기타 생활성 물질이 혼입된 수술용 봉합사
US20100098739A1 (en) * 2008-10-20 2010-04-22 University Of Virginia Patent Foundation Compositions and methods for modular soft tissue repair
US20100112696A1 (en) * 2008-11-03 2010-05-06 Baxter International Inc. Apparatus And Methods For Processing Tissue To Release Cells
US8309343B2 (en) * 2008-12-01 2012-11-13 Baxter International Inc. Apparatus and method for processing biological material
US20120020937A1 (en) * 2009-04-28 2012-01-26 Anterogen Co., Ltd. Autologous and allogenic adipose-derived stromal stem cell composition for treating fistulas
US9352003B1 (en) 2010-05-14 2016-05-31 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US8883210B1 (en) 2010-05-14 2014-11-11 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US10130736B1 (en) 2010-05-14 2018-11-20 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US9669200B2 (en) 2010-08-06 2017-06-06 Boston Scientific Scimed, Inc. Systems and methods for the treatment of pelvic disorders including magnetic particulates
US9180172B2 (en) 2010-12-15 2015-11-10 Ams Research Corporation Treatment of Peyronies disease
US8979797B2 (en) 2010-12-16 2015-03-17 Ams Research Corporation High pressure delivery system and method for treating pelvic disorder using large molecule therapeutics
ES2479544T1 (es) 2011-01-12 2014-08-20 Tigenix, S.A.U. Células madre mesenquimales derivadas de tejido adiposo para administración intralinfática en enfermedades autoimmunes e inflamatorias
US20140154227A1 (en) * 2011-03-11 2014-06-05 Javier Garcia Casado Cell populations having immunoregulatory activity, method for isolation and uses
US8834928B1 (en) 2011-05-16 2014-09-16 Musculoskeletal Transplant Foundation Tissue-derived tissugenic implants, and methods of fabricating and using same
CL2011001904A1 (es) * 2011-08-08 2012-03-09 Univ Pontificia Catolica Chile Formulacion farmaceutica que comprende celulas madres mesenquimales vivas suspendidas en un vehiculo farmaceuticamente aceptable, sistema de aplicacion topica en aerosol que las comprende; y su uso para tratar heridas.
US20130072903A1 (en) * 2011-09-20 2013-03-21 John Chapman Adipose Tissue Graft for Wound Healing
GB201202319D0 (en) * 2012-02-10 2012-03-28 Orbsen Therapeutics Ltd Stromal stem cells
US20140024011A1 (en) * 2012-07-23 2014-01-23 AdiCyte, Inc. Method for Preparing Adipose Tissue
ES2968961T3 (es) * 2012-10-18 2024-05-14 Mayo Found Medical Education & Res Técnicas para el tratamiento de abscesos
WO2014186854A1 (pt) * 2013-05-24 2014-11-27 Universidade Estadual De Campinas - Unicamp Processo de obtenção de fio de sutura enriquecido com celulas-tronco, fios obtidos, kit de sutura e seus usos
MX2016001247A (es) 2013-07-30 2016-08-17 Musculoskeletal Transplant Foundation Matrices derivadas de tejido suave acelular y metodos para preparar las mismas.
EP3224280A1 (en) 2014-11-26 2017-10-04 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
RU2588835C1 (ru) * 2014-11-27 2016-07-10 Олег Германович Макеев Способ терапии повреждений кожи и биотрансплантат для его осуществления
US10531957B2 (en) 2015-05-21 2020-01-14 Musculoskeletal Transplant Foundation Modified demineralized cortical bone fibers
US10912864B2 (en) 2015-07-24 2021-02-09 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
US11052175B2 (en) 2015-08-19 2021-07-06 Musculoskeletal Transplant Foundation Cartilage-derived implants and methods of making and using same
GB201604304D0 (en) * 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
EP3484485A1 (en) * 2016-07-12 2019-05-22 Centre National De La Recherche Scientifique Compositions useful for mucosal healing
IT201700043316A1 (it) * 2017-04-20 2018-10-20 Lipogems Int S P A Drug delivery system
JP6999918B2 (ja) 2017-08-21 2022-02-04 学校法人慶應義塾 血小板表面抗原と間葉系細胞表面抗原を共発現する血小板様細胞を含む創傷治癒促進剤
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
CN111840645B (zh) * 2020-07-29 2022-04-01 沈阳细胞治疗工程技术研发中心有限公司 一种瘘洞修补制剂及其制备方法
CN114949361A (zh) * 2021-12-31 2022-08-30 浙江金时代生物技术有限公司 一种用于子宫内膜修复的聚乳酸-羟基乙酸共聚物支架与人脐带间充质干细胞复合物的制备方法

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4298002A (en) 1979-09-10 1981-11-03 National Patent Development Corporation Porous hydrophilic materials, chambers therefrom, and devices comprising such chambers and biologically active tissue and methods of preparation
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5143842A (en) 1988-11-01 1992-09-01 The University Of Colorado Foundation, Inc. Media for normal human muscle satellite cells
US5145770A (en) 1990-06-04 1992-09-08 Biosurface Technology, Inc. Cryopreservation of cultured epithelial sheets
US5149543A (en) 1990-10-05 1992-09-22 Massachusetts Institute Of Technology Ionically cross-linked polymeric microcapsules
US6010696A (en) * 1990-11-16 2000-01-04 Osiris Therapeutics, Inc. Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells
US5733542A (en) 1990-11-16 1998-03-31 Haynesworth; Stephen E. Enhancing bone marrow engraftment using MSCS
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
BR9307217A (pt) 1992-10-10 1999-03-30 Hemscheidt Fahrwerktech Gmbh Sistema de suspenção hidropneumático
EP0672033B1 (en) 1992-12-02 1998-03-11 Shell Internationale Researchmaatschappij B.V. Azoxycyanobenzene derivatives
US5709854A (en) * 1993-04-30 1998-01-20 Massachusetts Institute Of Technology Tissue formation by injecting a cell-polymeric solution that gels in vivo
WO1995002698A1 (en) 1993-07-12 1995-01-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
CA2192103C (en) 1994-06-06 2002-02-05 Arnold I. Caplan Biomatrix for tissue regeneration
US6174333B1 (en) 1994-06-06 2001-01-16 Osiris Therapeutics, Inc. Biomatrix for soft tissue regeneration using mesenchymal stem cells
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
DE69634084T2 (de) 1995-06-07 2005-12-08 Inex Pharmaceuticals Corp. Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer
JPH11510698A (ja) 1995-08-04 1999-09-21 ザ ジェネラル ホスピタル コーポレイション トランスジェニックブタ及びヒトｈｌａ遺伝子を有するブタ細胞
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
US5705308A (en) 1996-09-30 1998-01-06 Eastman Kodak Company Infrared-sensitive, negative-working diazonaphthoquinone imaging composition and element
WO1998031316A1 (en) * 1997-01-17 1998-07-23 Celadon Science, Llc Methods for promoting healing of corneal resurfacing wounds
CN1166773C (zh) 1997-12-02 2004-09-15 泽恩比奥公司 分离的人脂肪组织衍生的基质细胞
IL137614A0 (en) 1998-02-04 2001-07-24 Gen Hospital Corp An inhibitor of a costimulatory pathway and hematopoietic stem cells for promoting graft acceptance
US6368636B1 (en) * 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
US9585916B2 (en) 1999-03-26 2017-03-07 Northern Therapeutics Inc. Cell based therapy for the pulmonary system
CA2326838C (en) 1998-04-03 2008-12-23 Osiris Therapeutics, Inc. Mesenchymal stem cells as immunosuppressants
US6546105B1 (en) 1998-10-30 2003-04-08 Matsushita Electric Industrial Co., Ltd. Sound image localization device and sound image localization method
US20050153442A1 (en) 1999-03-10 2005-07-14 Adam Katz Adipose-derived stem cells and lattices
US6777231B1 (en) 1999-03-10 2004-08-17 The Regents Of The University Of California Adipose-derived stem cells and lattices
US20030082152A1 (en) * 1999-03-10 2003-05-01 Hedrick Marc H. Adipose-derived stem cells and lattices
EP1165830B1 (en) 1999-03-10 2017-07-12 University of Pittsburgh of the Commonwealth System of Higher Education Adipose-derived stem cells and lattices
WO2000073418A2 (en) * 1999-05-28 2000-12-07 Pacgen Technologies Llc A method of using autologous fibroblasts to promote healing of wounds and fistulas
US7670628B2 (en) 1999-07-07 2010-03-02 Angioblast Systems, Inc. Mesenchymal precursor cell
US7078232B2 (en) * 1999-08-19 2006-07-18 Artecel, Inc. Adipose tissue-derived adult stem or stromal cells for the repair of articular cartilage fractures and uses thereof
US6555374B1 (en) 1999-08-19 2003-04-29 Artecel Sciences, Inc. Multiple mesodermal lineage differentiation potentials for adipose tissue-derived stromal cells and uses thereof
IL149933A0 (en) 1999-12-06 2002-11-10 Gen Hospital Corp Pancreatic stem cells and their use in transplantation
JP4680483B2 (ja) 2001-02-23 2011-05-11 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 組織および臓器の治療および修復に用いるための幹細胞マトリックスの迅速な調製方法
US20030054331A1 (en) 2001-09-14 2003-03-20 Stemsource, Inc. Preservation of non embryonic cells from non hematopoietic tissues
CZ2004695A3 (cs) 2001-11-09 2005-06-15 Artecel Sciences, Inc. Způsoby a kompozice pro použití buněk stromatu pro podporu embryonálních a dospělých kmenových buněk
AU2002346648A1 (en) * 2001-12-04 2003-06-17 Christopher J Woolverton Storage-stable fibrin sealant
US7771716B2 (en) 2001-12-07 2010-08-10 Cytori Therapeutics, Inc. Methods of using regenerative cells in the treatment of musculoskeletal disorders
ES2287447T3 (es) * 2002-02-19 2007-12-16 Medipost, Co., Ltd. Metodos de aislamiento y expansion del cultivo de celulas troncales/madre mesenquimatosas a partir de sangre del cordon umbilical, y metodo de diferenciacion de celulas troncales/madre mesenquimatosas derivadas de sangre del cordon umbilical en diversos tejidos mesenquimatosos.
WO2003077865A2 (en) 2002-03-15 2003-09-25 Baxter International Inc. Methods and compositions for directing cells to target organs
CA2489596A1 (en) * 2002-06-14 2003-12-24 Dyax Corporation Protein analysis
AU2003239016B2 (en) 2002-06-14 2007-09-20 Xintela Ab Marker for stem cells and its use
US20040101959A1 (en) * 2002-11-21 2004-05-27 Olga Marko Treatment of tissue with undifferentiated mesenchymal cells
JP2004190976A (ja) * 2002-12-12 2004-07-08 Sony Corp 熱輸送装置及び電子デバイス
NZ542127A (en) * 2003-02-13 2008-04-30 Anthrogenesis Corp Use of umbilical cord blood to treat individuals having a disease, disorder or condition
WO2004090112A2 (en) 2003-04-01 2004-10-21 United States Of America Department Of Veteran's Affairs Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure and renal dysfunction
ES2265199B1 (es) 2003-06-12 2008-02-01 Cellerix, S.L. Celulas madre adultas multipotentes procedentes de condrocitos desdiferenciados y sus aplicaciones.
ES2564044T3 (es) 2003-06-27 2016-03-17 DePuy Synthes Products, Inc. Células posparto derivadas de tejido del cordón umbilical y métodos de preparación y uso de las mismas
US7645229B2 (en) * 2003-09-26 2010-01-12 Armstrong David N Instrument and method for endoscopic visualization and treatment of anorectal fistula
KR20060036933A (ko) * 2003-10-07 2006-05-02 바이오마스터 인코포레이티드 지방-유래 전구세포의 세포 분화
EP1692275B1 (en) 2003-11-04 2010-12-29 Biomaster, Inc. Method and system for preparing stem cells from fat tissue
US7968126B2 (en) 2003-12-24 2011-06-28 The Trustees Of Columbia University In The City Of New York Creation of a biological atrioventricular bypass to compensate for atrioventricular block
JP2007530543A (ja) * 2004-03-22 2007-11-01 オシリス セラピューティクス，インコーポレイテッド 間葉幹細胞及びその使用法
US20080095749A1 (en) 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
RU2252252C1 (ru) 2004-04-09 2005-05-20 Тепляшин Александр Сергеевич Способ выделения мезенхимальных стволовых клеток
US20060045872A1 (en) * 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
ES2313805B1 (es) * 2004-10-04 2009-12-23 Cellerix, S.L. Identificacion y aislamiento de celulas multipotentes de tejido mesenquimal no osteocondral.
ES2264862B8 (es) 2004-08-25 2017-01-20 Cellerix, S.L. Biomaterial para sutura.
WO2006029347A2 (en) 2004-09-03 2006-03-16 University Of Maryland, Baltimore Integrin cd18 is a novel stromal stem cell marker and functions to promote osteogenesis
WO2006110582A1 (en) 2005-04-08 2006-10-19 Xcyte Therapies, Inc. Compositions and methods for the treatment of burns and sepsis
EP3184630B1 (en) 2005-09-23 2019-07-17 TiGenix, S.A.U. Cell populations having immunoregulatory activity, method for isolation and uses
EP1795588A1 (en) 2005-12-07 2007-06-13 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
US20120269774A1 (en) 2006-09-21 2012-10-25 Medistem Laboratories, Inc Allogeneic stem cell transplants in non-conditioned recipients
US20110262402A1 (en) 2007-09-07 2011-10-27 Masahiko Kuroda Therapeutic and prophylactic agents for arthritis
WO2009037690A1 (en) 2007-09-19 2009-03-26 Pluristem Ltd. Adherent cells from adipose or placenta tissues and use thereof in therapy
US20100247577A1 (en) 2007-10-17 2010-09-30 Txcell Tr1 cells, mesenchymal stem cells and uses thereof
GB0814249D0 (en) 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells
ES2345867B1 (es) 2009-04-03 2011-07-28 Fundacion Instituto Mediterraneo Para La Biotecnologia Y La Investigacion Sanitaria (Imabis) Celulas madre multipotentes derivadas de estroma de mesenterio.
US20120020937A1 (en) 2009-04-28 2012-01-26 Anterogen Co., Ltd. Autologous and allogenic adipose-derived stromal stem cell composition for treating fistulas
PL2451943T3 (pl) 2009-07-09 2017-04-28 Tigenix, S.A.U. Sposoby i kompozycje do zastosowania w terapiach komórkowych
ES2479544T1 (es) 2011-01-12 2014-08-20 Tigenix, S.A.U. Células madre mesenquimales derivadas de tejido adiposo para administración intralinfática en enfermedades autoimmunes e inflamatorias
US20140154227A1 (en) 2011-03-11 2014-06-05 Javier Garcia Casado Cell populations having immunoregulatory activity, method for isolation and uses
US20140134140A1 (en) 2012-11-09 2014-05-15 Case Western Reserve University Mesenchymal stem cell compositions for the treatment of microbial infections
ES2748825T3 (es) 2013-03-15 2020-03-18 Tigenix S A U Biomarcadores de linfocitos para determinar la respuesta clínica a la terapia celular
JP6412933B2 (ja) 2013-06-25 2018-10-24 ティジェニクス エス．エー．ユー． 免疫調節活性を有する細胞集団、その調製方法および使用
GB201604304D0 (en) * 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease

Also Published As

Publication number Publication date
EP2944688A1 (en) 2015-11-18
CY2018026I1 (el) 2020-05-29
PT2944688T (pt) 2018-01-19
DK2944688T3 (en) 2018-01-02
JP6545624B2 (ja) 2019-07-17
US20100098669A1 (en) 2010-04-22
PL2292737T5 (pl) 2019-05-31
CA2613457A1 (en) 2006-12-28
RU2435846C2 (ru) 2011-12-10
SI2944688T1 (en) 2018-07-31
RU2008102643A (ru) 2009-07-27
EP3176256B1 (en) 2018-08-15
JP2020141692A (ja) 2020-09-10
US20200206274A1 (en) 2020-07-02
LT2944688T (lt) 2018-02-26
US20190269737A1 (en) 2019-09-05
WO2006136244A2 (en) 2006-12-28
PL3176255T3 (pl) 2019-05-31
EP3176257A1 (en) 2017-06-07
CA2613457C (en) 2015-12-01
EP3176257B1 (en) 2018-08-22
EP2292737A1 (en) 2011-03-09
JP7027484B2 (ja) 2022-03-01
NL300953I1 (ru) 2018-10-03
DK2292737T3 (en) 2015-05-26
PT3176255T (pt) 2018-11-28
CN101263224A (zh) 2008-09-10
EP2292737B1 (en) 2015-03-25
LTPA2018514I1 (lt) 2018-10-10
NL300953I2 (nl) 2021-02-03
JP2008546397A (ja) 2008-12-25
HUE025338T2 (en) 2016-02-29
EP3176254A1 (en) 2017-06-07
BRPI0613811B1 (pt) 2021-03-02
EP3176254B1 (en) 2021-04-21
ES2696536T3 (es) 2019-01-16
PL2292737T3 (pl) 2015-10-30
PT2292737E (pt) 2015-07-06
CY1116764T1 (el) 2017-03-15
LTC2292737I2 (lt) 2021-05-25
JP2016116523A (ja) 2016-06-30
JP6289858B2 (ja) 2018-03-07
NZ565246A (en) 2011-09-30
HUE036590T2 (hu) 2018-07-30
US20120213750A1 (en) 2012-08-23
AU2006261383A1 (en) 2006-12-28
LT3176255T (lt) 2019-01-10
PL2944688T3 (pl) 2018-05-30
CN103143055A (zh) 2013-06-12
SI3176255T1 (sl) 2019-01-31
IL188378A0 (en) 2008-04-13
KR20080036588A (ko) 2008-04-28
EP2292737B2 (en) 2018-07-04
US20170189452A1 (en) 2017-07-06
RU2744977C2 (ru) 2021-03-17
CY1119853T1 (el) 2018-06-27
ES2538657T5 (es) 2018-09-14
US11672831B2 (en) 2023-06-13
US20150065948A1 (en) 2015-03-05
SI2292737T2 (sl) 2018-09-28
US20060045872A1 (en) 2006-03-02
AU2006261383B2 (en) 2012-03-22
US11660318B2 (en) 2023-05-30
EP1899458A2 (en) 2008-03-19
JP2014054550A (ja) 2014-03-27
ES2538657T3 (es) 2015-06-23
ES2880349T3 (es) 2021-11-24
US20170189451A1 (en) 2017-07-06
US10758575B2 (en) 2020-09-01
CY2018026I2 (el) 2020-05-29
WO2006136244A3 (en) 2007-03-15
HUS1800039I1 (hu) 2018-10-29
SG166770A1 (en) 2010-12-29
BRPI0613811B8 (pt) 2021-07-27
RU2016152229A (ru) 2018-07-03
BRPI0613811A2 (pt) 2011-02-15
JP2019088310A (ja) 2019-06-13
ES2655287T3 (es) 2018-02-19
EP3176256A1 (en) 2017-06-07
US8999709B2 (en) 2015-04-07
IL188378A (en) 2013-03-24
US20140072539A1 (en) 2014-03-13
DK3176254T3 (da) 2021-07-12
RU2016152229A3 (ru) 2020-04-29
EP3176255A1 (en) 2017-06-07
ES2696535T3 (es) 2019-01-16
DK3176255T3 (en) 2018-11-19
RU2608641C2 (ru) 2017-01-23
JP6812475B2 (ja) 2021-01-13
ES2696537T3 (es) 2019-01-16
EP2944688B1 (en) 2017-10-25
DK2292737T4 (en) 2018-10-08
US20170209496A1 (en) 2017-07-27
NZ594848A (en) 2012-05-25
US10780132B2 (en) 2020-09-22
US10548924B2 (en) 2020-02-04
LUC00085I2 (ru) 2018-11-26
EP3176255B1 (en) 2018-08-22
SI2292737T1 (sl) 2015-10-30

Similar Documents

Publication Publication Date Title
RU2011135234A (ru) Применение стромальных стволовых клеток жировой ткани для лечения свищей
JP2014054550A5 (ru)
Lombaert et al. Concise review: salivary gland regeneration: therapeutic approaches from stem cells to tissue organoids
Chun et al. Preparation and characterization of human adipose tissue-derived extracellular matrix, growth factors, and stem cells: a concise review
Mafi et al. Suppl 2: Adult mesenchymal stem cells and cell surface characterization-A systematic review of the literature
Domenis et al. Adipose tissue derived stem cells: in vitro and in vivo analysis of a standard and three commercially available cell-assisted lipotransfer techniques
JP2008546397A5 (ru)
JP2020533021A5 (ru)
Celebi et al. Effects of extracellular matrix proteins on the growth of haematopoietic progenitor cells
Kishimoto et al. Dedifferentiated Fat (DFAT) cells: A cell source for oral and maxillofacial tissue engineering
AU2022241581A1 (en) Compositions comprising mesenchymal stem cells and uses thereof
Sharath et al. Human adipose tissue derivatives as a potent native biomaterial for tissue regenerative therapies
Purwaningrum et al. Comparative characteristic study from bone marrow-derived mesenchymal stem cells
EP3943065A1 (en) Injection formulation composition containing mesenchymal stem cell-hydrogel and method for preparing, freezing and defrosting same
Jessop et al. Tissue specific stem/progenitor cells for cartilage tissue engineering: A systematic review of the literature
Xu et al. Current and future uses of skeletal stem cells for bone regeneration
Minjuan et al. Hair Follicle Morphogenesis in the Treatment of Mouse Full‐Thickness Skin Defects Using Composite Human Acellular Amniotic Membrane and Adipose Derived Mesenchymal Stem Cells
Stolzing et al. Effect of age and diabetes on the response of mesenchymal progenitor cells to fibrin matrices
Choi et al. Prochondrogenic effect of decellularized extracellular matrix secreted from human induced pluripotent stem cell-derived chondrocytes
Urkasemsin et al. Unveiling stem cell heterogeneity toward the development of salivary gland regenerative strategies
Volpe et al. Mesenchymal stromal cells from adipose tissue attached to suture material enhance the closure of enterocutaneous fistulas in a rat model
Pawitan et al. Adipose-derived stem cells and their microenvironment (Niche) in type 2 diabetes mellitus
Samiei et al. Isolation and characterization of dental pulp stem cells from primary and permanent teeth
SG162750A1 (en) Semi-solid osteoblast composition containing fibrin for bone union and method preparing the same
EP3778873A1 (en) Method for isolating stem cells from human umbilical cord